Emergent to acquire Trubion for $96.8 million plus milestones
This article was originally published in Scrip
Executive Summary
Shares in Trubion Pharmaceuticals jumped nearly 50% on news of a definitive agreement to be acquired by Emergent BioSolutions, the US company specialising in immunobiotics for biodefence applications and commercial use against infectious diseases.